Detecting Xylazine: Prevalence, Pharmacokinetics, and Analytical Considerations

Area of Science:

• Forensic Toxicology
• Pharmacology
• Public Health

Background:

• Xylazine, a veterinary alpha-2 adrenergic agonist, is increasingly detected in the illicit drug supply.
• Its presence is associated with rising opioid-related overdose deaths.
• Current clinical testing for xylazine is limited, with no point-of-care assays available.

Purpose of the Study:

• To address the urgent need for accessible xylazine detection methods.
• To prioritize the development of timely and cost-effective assays for acute xylazine toxicity.
• To reduce the harms associated with xylazine in the illicit drug supply.

Main Methods:

• Review of existing mass spectrometry-based detection methods for xylazine.
• Analysis of the limitations of current clinical laboratory testing.
• Identification of the need for point-of-care diagnostic tools.

Main Results:

• Several mass spectrometry methods for xylazine detection exist.
• Routine clinical laboratory testing for xylazine is not widespread.
• Point-of-care assays for acute xylazine toxicity are currently unavailable.

Conclusions:

• The increasing prevalence of xylazine in illicit drugs necessitates improved detection strategies.
• Development of rapid, cost-effective diagnostic tools is a priority.
• Enhanced clinical and point-of-care testing will aid in mitigating xylazine-related harms.